In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on ImmunoGen (IMGN – Research Report), with a price target of $12.00. The company's shares closed last Friday at $4.74. According to TipRanks.com, Ramakanth has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -2.9% and a 34.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Janux Therapeutics Inc, and Corcept Therapeutics. Currently, the analyst consensus on ImmunoGen is a Moderate Buy with an average price target of $15.00. See Insiders’ Hot Stocks on TipRanks >> ImmunoGen's market cap is currently $1.
https://www.tipranks.com/news/blurbs/immunogen-imgn-gets-a-buy-rating-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more ImmunoGen Charts.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more ImmunoGen Charts.